Tlwm lifted its position in shares of Medtronic plc (NYSE:MDT) by 39.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,250 shares of the medical technology company’s stock after purchasing an additional 2,052 shares during the period. Tlwm’s holdings in Medtronic were worth $897,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of MDT. Grandview Asset Management LLC acquired a new stake in Medtronic in the first quarter valued at $25,000. Solstein Capital LLC bought a new stake in Medtronic during the first quarter valued at $33,000. Altshuler Shaham Ltd bought a new stake in Medtronic during the first quarter valued at $34,000. Corbenic Partners LLC increased its stake in Medtronic by 264.2% during the second quarter. Corbenic Partners LLC now owns 295 shares of the medical technology company’s stock valued at $37,000 after purchasing an additional 214 shares during the last quarter. Finally, Aspire Private Capital LLC increased its stake in Medtronic by 1,316.7% during the first quarter. Aspire Private Capital LLC now owns 340 shares of the medical technology company’s stock valued at $40,000 after purchasing an additional 316 shares during the last quarter. 79.59% of the stock is currently owned by institutional investors and hedge funds.
In related news, CEO Geoffrey Martha sold 11,500 shares of the stock in a transaction that occurred on Monday, June 28th. The stock was sold at an average price of $125.29, for a total value of $1,440,835.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Bradley E. Lerman sold 50,775 shares of the stock in a transaction that occurred on Tuesday, August 31st. The stock was sold at an average price of $134.17, for a total value of $6,812,481.75. The disclosure for this sale can be found here. Insiders sold a total of 106,390 shares of company stock worth $14,140,470 in the last quarter. 0.47% of the stock is owned by corporate insiders.
Medtronic (NYSE:MDT) last posted its quarterly earnings data on Monday, August 23rd. The medical technology company reported $1.41 EPS for the quarter, beating analysts’ consensus estimates of $1.32 by $0.09. Medtronic had a net margin of 12.29% and a return on equity of 13.85%. The company had revenue of $7.99 billion during the quarter, compared to analyst estimates of $7.88 billion. During the same period in the prior year, the firm earned $0.62 earnings per share. The business’s quarterly revenue was up 22.7% on a year-over-year basis. Equities research analysts expect that Medtronic plc will post 5.7 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 15th. Stockholders of record on Friday, September 24th will be issued a $0.63 dividend. The ex-dividend date is Thursday, September 23rd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.91%.
Several analysts have weighed in on the stock. Barclays assumed coverage on shares of Medtronic in a research note on Monday, May 24th. They set an “equal weight” rating and a $145.00 target price for the company. upped their price target on shares of Medtronic from $133.00 to $143.00 and gave the stock a “buy” rating in a research report on Friday, May 28th. Argus upped their price target on shares of Medtronic from $150.00 to $165.00 and gave the stock a “buy” rating in a research report on Friday, August 27th. Credit Suisse Group increased their target price on shares of Medtronic from $137.00 to $146.00 and gave the company an “outperform” rating in a research report on Wednesday, August 25th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on shares of Medtronic from $134.00 to $149.00 and gave the company a “buy” rating in a research report on Friday, May 28th. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $144.18.
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group.
Featured Story: Equal Weight Rating
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc (NYSE:MDT).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.